New Research In The Treatment Of Pain In Joint Diseases

2023 Author: Philip Bishop | [email protected]. Last modified: 2023-08-03 19:28

Treatment of pain syndrome in diseases of the joints

Pain and inflammation are constant and integral manifestations of the vast majority of pathological conditions in the human body. With lesions of the musculoskeletal system, they necessarily take place both in acute trauma and in chronic diseases. The authors of numerous publications devoted to the diagnosis and treatment of joint diseases, for the most part, agree that an integrated approach is needed that harmoniously combines several well-known methods, both conservative and operative. However, with any chosen treatment strategy, up to endoprosthetics, almost all patients take medications that have anti-inflammatory and analgesic effects ^[5-7]… Pain syndrome is a mandatory manifestation of articular pathology. In some cases, especially at relatively early stages of the development of the pathological process, patients do not present any complaints at all - only pain. And it is the pain that makes them start treatment.

Current understanding of the pathogenesis of chronic pain syndrome includes three main types of pain:

• nociceptive,
• neuropathic,
• dysfunctional.

Rheumatologists are familiar with nociceptive pain associated with the activation of nociceptors during inflammation, trauma, burns, etc. Neuropathic pain, in turn, is associated with damage to the somatosensory nervous system at any level, from peripheral nerves to the cerebral cortex and descending analgesic (antinociceptive) systems. The third type of pain - dysfunctional pain, previously called psychogenic, is not associated with either inflammation or damage to the somatosensory nervous system; it occurs due to dysfunction of pain systems, namely, due to a violation of pain modulation. A common mechanism that maintains all types of pain in a chronic state is central sensitization (CS), an increased reactivity of central nociceptive neurons, the end result of which is increased pain.

Chronic inflammation rearranges the work of pain-relieving systems, which underlies the involvement of neurogenic mechanisms in the pathogenesis of chronic pain syndrome in rheumatic diseases, determining its intensity and qualitative characteristics. Damage to the joints and surrounding tissues leads to the release of inflammatory mediators. Activation of arachidonic acid leads to the production of prostaglandins and leukotrienes; immune cells move towards the lesion and secrete inflammatory mediators, including cytokines, including tumor necrosis factor (TNF) ^[9]… During inflammation, the primary afferent neurons, the fibers of which innervate the joint, become hypersensitive (sensitized). In response to pressure and movement, non-painful mechanoreceptors (α-beta fibers), which, as a rule, have a low activation threshold, are excited. Nociceptors (α-delta fibers and C-fibers), which have a high threshold, begin to respond to light pressure and movement, and "silent" nociceptors become "responsive" to mechanical stimuli. The result of such neuroplastic changes is the activation of the nociceptive system by ordinary, painless stimuli, ie, peripheral sensitization of nociceptors occurs ^[9].

The modern concept of pain relief, especially chronic pain, is a flexible multicomponent therapy aimed at various links of pathogenesis, including the use of NSAIDs, opioid analgesics, local anesthetics, muscle relaxants, etc. A separate and complex topic is timely diagnosis and adequate specific therapy for the neuropathic component of chronic pain. NSAIDs are undoubtedly the most popular and convenient drug used to initiate empiric therapy for joint pain. The effectiveness of NSAIDs in the treatment of joint diseases is beyond doubt. This fact was confirmed by the results of a recent meta-analysis by Cochran (2008), which assessed the therapeutic potential of NSAIDs in acute and chronic low back pain (LBP). For the analysis, the authors used data from 65 randomized controlled trials (RCTs), which included a total of 11,237 patients. At least 40% of the RCTs included in the meta-analysis met the criteria for work of good methodological quality. Based on the study, Cochran experts made an unequivocal conclusion: NSAIDs are indeed effective for the relief of both acute and chronic MNP.

When choosing NSAIDs, one should be guided not only by the effectiveness of the drug, but also by the safety of use. Therefore, preference is given to the group of NSAIDs COX-2 selective action.

The following groups of COX-2 inhibitors are registered in the Russian Federation:

• Sulfonanilide derivatives (nimesulide).
• Representatives of coxibs (etoricoxib).
• Oxicam derivatives (meloxicam).

Etoricoxib is the most selective NSAID. This selective COX-2 inhibitor in therapeutic concentrations blocks the formation of prostaglandins and has a pronounced anti-inflammatory and analgesic effect. Selective inhibition of COX-2 is accompanied by a decrease in the severity of clinical symptoms of osteoarthritis, while there is no effect on platelet function and the gastrointestinal mucosa.

The best evidence of the high efficacy of etoricoxib for the treatment of pain syndrome of articular etiology was the study by D. van der Heijde et al. In the course of this study, 387 patients with ankylosing spondyloarthritis received etoricoxib 90 and 120 mg / day, naproxen 1000 mg / day, or placebo for 1 year. The effect of NSAIDs was assessed in relation to the severity of back pain, disease activity, and dynamics of spinal function. In all respects, etoricoxib was superior to placebo and overall (in both dosages) was more effective than the reference drug ^[10].

Etorelex is the first Russian Etoricoxib. It is effective against the most common types of joint pain. At the same time, the variability of dosages allows you to choose the necessary form for a particular patient with pain syndrome. Etorelex acts selectively, so the number of side effects is minimal. The drug is more affordable than foreign analogues, which increases the compliance of therapy. Etorelex is a modern, safe pain management at an affordable price.

Sources of information:

1. Hochman JR, French MR, Bermingham SL, Hawker GA Th e nerve of osteoarthritis pain // Arthritis Care Res (Hoboken). 2010. Vol. 62 (7). P. 1019-1023. doi: 10.1002 / acr.20142.

2. Arendt-Nielsen L., Nie H., Laursen MB et al. Sensitization in patients with painful knee osteoarthritis // Pain. 2010. Vol. 149 (3). P. 573-581. doi: 10.1016 / j. pain.2010.04.003.
3. Imamura M., Imamura ST, Kaziyama HH et al. Impact of nervous system hyperalgesia on pain, disability, and quality of life in patients with knee osteoarthritis: a controlled analysis // Arthritis Rheum. 2008. Vol. 59 (10). P. 1424-1431. doi: 10.1002 / art.24120.
4. Kalk NJ, Schweinhardt P. et al. Functional magnetic resonance imaging of central processing of clinical and experimental pain in rheumatoid arthritis // Abstracts 11th world congress on pain. 2005. Sydney, Australia. P. 108.

5. Filatova ES, Turovskaya EF, Erdes Sh. F. et al. Analysis of the clinical characteristics of neurogenic pain syndrome in patients with rheumatoid arthritis and osteoarthritis of the knee joints // Russian Journal of Pain. 2014. No. 1 (42). Pp. 64–65 [Filatova ES, Turovskaja EF, Jerdes Sh. F. i dr. Analiz klinicheskih harakteristik nevrogennogo bolevogo sindroma u bol'nyh revmatoidnym artritom i osteoartrozom kolennyh sustavov // Rossijskij zhurnal boli. 2014. No. 1 (42). S. 64–65 (in Russian)].
6. Filatova E.., Turovskaya EF, Alekseeva LI et al. Features of chronic pain syndrome of various rheumatic diseases // Consilium Medicum. Neurology and rheumatology (App.). 2016. No. 2. P. 22–25 [Filatova ES, Turovskaja EF, Alekseeva LI i dr. Osobennosti hronicheskogo bolevogo sindroma razlichnyh revmaticheskih zabolevanij // Consilium Medicum. Nevrologija i revmatologija (Pril.). 2016. No. 2. S. 22–25 (in Russian)].
7. Kidd BL Osteoarthritis and joint pain // Pain. 2006. Vol. 123. P. 6-9.
8. Sofat N., Ejindu V., Kiely R. What makes osteoarthritis painful? Th e evidence for Local and Central pain processing // Rheumatology. 2011. Vol. 50 (12). P. 2157-2165.
9. Wylde V., Hewlett S., Learmonth ID, Dieppe R. Persistant pain aft er joint replacement: Prevalence, sensory qualities, and postoperative determinants // Pain. 2011. Vol. 152. P. 566-572.
10. Van der Heijde D., Baraf H., Ramos-Remus C. et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005; 52 (4): 1205-15.